A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine

Measles, mumps, and rubella (MMR) are highly infectious viral diseases affecting young children and have high secondary attack rates. Present MMR vaccines show consistent seroconversion rates for anti-measles and anti-rubella antibodies with variable responses for anti-mumps antibodies. Most common...

Full description

Saved in:
Bibliographic Details
Main Authors: Nitin Shah, Apurba Ghosh, Kishore Kumar, Trayambak Dutta, Manish Mahajan
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2302685
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849689037994983424
author Nitin Shah
Apurba Ghosh
Kishore Kumar
Trayambak Dutta
Manish Mahajan
author_facet Nitin Shah
Apurba Ghosh
Kishore Kumar
Trayambak Dutta
Manish Mahajan
author_sort Nitin Shah
collection DOAJ
description Measles, mumps, and rubella (MMR) are highly infectious viral diseases affecting young children and have high secondary attack rates. Present MMR vaccines show consistent seroconversion rates for anti-measles and anti-rubella antibodies with variable responses for anti-mumps antibodies. Most common strains for MMR vaccines, currently available in India, are the Edmonston-Zagreb measles strain, Leningrad Zagreb (L-Z) mumps strain, and the RA 27/3 rubella strain. L-Z strain of mumps virus has been found to be associated with aseptic meningitis by different studies from different parts of the world including India. Recently, a novel freeze-dried MMR vaccine developed by Zydus Lifesciences (Zyvac MMR) contains Edmonston Zagreb measles strain, Hoshino mumps strain, and RA 27/3 rubella strain. The Hoshino strain is WHO approved and was found to induce interferon gamma production. This review article aims to provide a comprehensive appraisal of the data available on the safety and immunogenicity of the novel MMR vaccine.
format Article
id doaj-art-7093428b00aa48bc8099b3038e06a76e
institution DOAJ
issn 2164-5515
2164-554X
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj-art-7093428b00aa48bc8099b3038e06a76e2025-08-20T03:21:46ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2302685A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccineNitin Shah0Apurba Ghosh1Kishore Kumar2Trayambak Dutta3Manish Mahajan4Department of Peadiatrics, P.D Hinduja Hospital & Medical Research Centre, Mumbai, IndiaDepartment of Peadiatrics, Institute of Child Health, Kolkata, IndiaDepartment of Peadiatrics, CloudNine Group of Hospitals, Bengaluru, IndiaMedical Affairs, Zydus Lifesciences Ltd., Zydus Corporate Park, Ahmedabad, IndiaMedical Affairs, Zydus Lifesciences Ltd., Zydus Corporate Park, Ahmedabad, IndiaMeasles, mumps, and rubella (MMR) are highly infectious viral diseases affecting young children and have high secondary attack rates. Present MMR vaccines show consistent seroconversion rates for anti-measles and anti-rubella antibodies with variable responses for anti-mumps antibodies. Most common strains for MMR vaccines, currently available in India, are the Edmonston-Zagreb measles strain, Leningrad Zagreb (L-Z) mumps strain, and the RA 27/3 rubella strain. L-Z strain of mumps virus has been found to be associated with aseptic meningitis by different studies from different parts of the world including India. Recently, a novel freeze-dried MMR vaccine developed by Zydus Lifesciences (Zyvac MMR) contains Edmonston Zagreb measles strain, Hoshino mumps strain, and RA 27/3 rubella strain. The Hoshino strain is WHO approved and was found to induce interferon gamma production. This review article aims to provide a comprehensive appraisal of the data available on the safety and immunogenicity of the novel MMR vaccine.https://www.tandfonline.com/doi/10.1080/21645515.2024.2302685MMRIndiaHoshinoLeningrad ZagrebIAPaseptic meningitis
spellingShingle Nitin Shah
Apurba Ghosh
Kishore Kumar
Trayambak Dutta
Manish Mahajan
A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine
Human Vaccines & Immunotherapeutics
MMR
India
Hoshino
Leningrad Zagreb
IAP
aseptic meningitis
title A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine
title_full A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine
title_fullStr A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine
title_full_unstemmed A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine
title_short A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine
title_sort review of safety and immunogenicity of a novel measles mumps rubella mmr vaccine
topic MMR
India
Hoshino
Leningrad Zagreb
IAP
aseptic meningitis
url https://www.tandfonline.com/doi/10.1080/21645515.2024.2302685
work_keys_str_mv AT nitinshah areviewofsafetyandimmunogenicityofanovelmeaslesmumpsrubellammrvaccine
AT apurbaghosh areviewofsafetyandimmunogenicityofanovelmeaslesmumpsrubellammrvaccine
AT kishorekumar areviewofsafetyandimmunogenicityofanovelmeaslesmumpsrubellammrvaccine
AT trayambakdutta areviewofsafetyandimmunogenicityofanovelmeaslesmumpsrubellammrvaccine
AT manishmahajan areviewofsafetyandimmunogenicityofanovelmeaslesmumpsrubellammrvaccine
AT nitinshah reviewofsafetyandimmunogenicityofanovelmeaslesmumpsrubellammrvaccine
AT apurbaghosh reviewofsafetyandimmunogenicityofanovelmeaslesmumpsrubellammrvaccine
AT kishorekumar reviewofsafetyandimmunogenicityofanovelmeaslesmumpsrubellammrvaccine
AT trayambakdutta reviewofsafetyandimmunogenicityofanovelmeaslesmumpsrubellammrvaccine
AT manishmahajan reviewofsafetyandimmunogenicityofanovelmeaslesmumpsrubellammrvaccine